Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Isoda A et al. Int J Hematol. 2016 Nov 21. [Epub ahead of print]. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Kurtz JE et al. Onco Targets Ther. 2016 Oct 28;9:6689-6693. eCollection 2016. Percutaneous sacroplasty…
DetailsSecondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients. Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print]. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print]. Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors. Jouni H et al. Am J…
DetailsPatients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print]. Absence…
DetailsA study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
DetailsThe Myeloma UK Clinical Trial Network (CTN) has achieved another significant milestone with data from the MUK six trial published in the latest issue of Lancet Haematology. MUK six, a Phase I/II multicentre open label trial aimed to determine the safety and both the optimum and maximum dose of panobinostat when used in combination with once-weekly Velcade,…
Details
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oliva S et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12641. [Epub ahead of print]. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Sonmezoglu K et al. Nucl Med Commun. 2016 Oct 21. [Epub ahead of print]. Whole body magnetic resonance imaging in…
DetailsUnravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F et al. Kidney Int. 2016 Oct 20. pii: S0085-2538(16)30487-2. doi: 10.1016/j.kint.2016.09.004. [Epub ahead of print]. Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity? Ravindran A et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):588-592. doi: 10.1016/j.clml.2016.08.004. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Ravindran A et al. Blood Cancer…
DetailsMyeloma CARs are rolling into the clinical arena. Hudecek M et al. Blood. 2016 Sep 29;128(13):1667-8. doi: 10.1182/blood-2016-08-729467. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Bilotti E et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood. 2016 Oct 4. pii: blood-2016-05-717769. [Epub ahead of…
Details